HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joseph Gligorov Selected Research

Adjuvant Chemotherapy

8/2017Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
4/2017Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study.
10/2014[Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey].
10/2012[Cost-effectiveness of a chemotherapy predictive test].
1/2012Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France.
3/2011Discordance with local guidelines for adjuvant chemotherapy in breast cancer: reasons and effect on survival.
5/2007Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views.
1/2006Taxane therapy for early stage breast cancer.
11/2004[Malignant cardiac tumors].
4/2004[Treatment of hot flashes in women with a previous diagnosis of breast cancer].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joseph Gligorov Research Topics

Disease

72Breast Neoplasms (Breast Cancer)
08/2022 - 08/2002
36Neoplasms (Cancer)
02/2022 - 08/2002
9Neoplasm Metastasis (Metastasis)
01/2018 - 11/2004
5Cardiotoxicity
08/2022 - 11/2004
5Disease Progression
12/2017 - 12/2008
5Hypertension (High Blood Pressure)
11/2015 - 05/2008
4Inflammatory Breast Neoplasms
04/2016 - 12/2004
4Renal Insufficiency (Renal Failure)
03/2012 - 09/2007
4Lung Neoplasms (Lung Cancer)
01/2009 - 08/2002
3COVID-19
06/2021 - 01/2020
3Proteinuria
11/2015 - 10/2014
3Osteonecrosis (Kienbock's Disease)
03/2012 - 12/2007
2Infections
01/2021 - 12/2007
2Ovarian Neoplasms (Ovarian Cancer)
10/2016 - 01/2016
2Pathologic Complete Response
03/2015 - 04/2012
2Hand-Foot Syndrome
11/2014 - 10/2014
2Bone Diseases (Bone Disease)
12/2008 - 12/2007
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2021
1Thrombosis (Thrombus)
06/2021
1Hemorrhage
06/2021
1Circulating Neoplastic Cells
01/2021
1Chronic Disease (Chronic Diseases)
01/2020
1Triple Negative Breast Neoplasms
09/2019
1Stomach Neoplasms (Stomach Cancer)
10/2018
1Body Weight (Weight, Body)
10/2018
1Pain (Aches)
12/2017
1Thromboembolism
11/2017
1Venous Thromboembolism
11/2017
1Sudden Infant Death (SID)
08/2017
1Ductal Carcinoma
02/2017
1Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
10/2016

Drug/Important Bio-Agent (IBA)

26Trastuzumab (Herceptin)FDA Link
08/2022 - 11/2004
11Hormones (Hormone)IBA
12/2021 - 12/2008
9Taxoids (Taxanes)IBA
09/2021 - 01/2004
9Docetaxel (Taxotere)FDA Link
01/2016 - 08/2002
8AnthracyclinesIBA
09/2021 - 01/2004
8Bevacizumab (Avastin)FDA Link
04/2016 - 01/2012
7ErbB Receptors (EGF Receptor)IBA
08/2022 - 01/2012
7Paclitaxel (Taxol)FDA LinkGeneric
01/2020 - 01/2004
7Biological ProductsIBA
11/2017 - 11/2007
6taxaneIBA
01/2017 - 01/2004
5Biomarkers (Surrogate Marker)IBA
01/2021 - 12/2014
5Diphosphonates (Bisphosphonates)IBA
03/2012 - 12/2007
5CreatinineIBA
03/2012 - 09/2007
5Pharmaceutical PreparationsIBA
03/2012 - 08/2002
44-azidobenzylcarazolol (pABC)IBA
02/2022 - 08/2012
4Tyrosine Kinase InhibitorsIBA
12/2021 - 11/2017
4Letrozole (Femara)FDA LinkGeneric
12/2021 - 01/2006
4Estrogen ReceptorsIBA
12/2017 - 08/2015
4Aromatase InhibitorsIBA
11/2010 - 01/2006
3GemcitabineFDA Link
09/2019 - 08/2002
3pertuzumabIBA
01/2018 - 01/2016
3Monoclonal AntibodiesIBA
11/2017 - 08/2005
3TamoxifenFDA LinkGeneric
12/2007 - 01/2006
2human ERBB2 proteinIBA
08/2022 - 01/2017
2Fulvestrant (Faslodex)FDA Link
12/2021 - 04/2017
2liposomal doxorubicin (Doxil)FDA Link
09/2021 - 11/2020
2EnzymesIBA
06/2021 - 01/2018
2Citric Acid (Citrate)FDA LinkGeneric
06/2021 - 01/2018
2Carboplatin (JM8)FDA LinkGeneric
09/2019 - 07/2007
2Proteins (Proteins, Gene)FDA Link
01/2018 - 07/2005
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2015 - 10/2014
2Capecitabine (Xeloda)FDA Link
11/2014 - 01/2012
2Doxorubicin (Adriamycin)FDA LinkGeneric
06/2013 - 12/2008
2Antineoplastic Agents (Antineoplastics)IBA
12/2008 - 08/2005
2Epidermal Growth Factor (EGF)IBA
07/2007 - 08/2005
2exemestane (Aromasin)FDA Link
09/2006 - 01/2006
2Anastrozole (Arimidex)FDA LinkGeneric
09/2006 - 01/2006
1palbociclibIBA
12/2021
1Cyclin-Dependent Kinase 4IBA
12/2021
1neratinibIBA
12/2021
1dimemorfan (AT 17)IBA
01/2021
1Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2021
1VaccinesIBA
01/2021
1Ado-Trastuzumab EmtansineIBA
11/2020
1Antiviral Agents (Antivirals)IBA
01/2020
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2020
1iniparibIBA
09/2019
1Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2019
1AntigensIBA
01/2018
1Indicators and Reagents (Reagents)IBA
01/2018
1Biosimilar PharmaceuticalsIBA
01/2018
1Carcinoembryonic AntigenIBA
01/2018
1AntibodiesIBA
11/2017
1Bispecific AntibodiesIBA
11/2017
1Lapatinib (GW572016)FDA Link
11/2017
1Alkylating AgentsIBA
10/2016

Therapy/Procedure

42Therapeutics
08/2022 - 04/2004
30Drug Therapy (Chemotherapy)
08/2022 - 11/2004
10Adjuvant Chemotherapy
08/2017 - 04/2004
7Neoadjuvant Therapy
04/2016 - 07/2007
5Radiotherapy
04/2017 - 11/2004
3Salvage Therapy
01/2018 - 01/2016
2Aftercare (After-Treatment)
10/2014 - 11/2009
2Drug Tapering
12/2010 - 10/2009
1Critical Care (Surgical Intensive Care)
06/2021
1Continuity of Patient Care
12/2020
1Precision Medicine
12/2018
1Splenectomy
12/2017
1Central Venous Catheters
11/2017